SecBot SecBot

CPPTL

Copper Property CTL Pass Through Trust
OTC· Real Estate· Inc. NY· CIK 0001837671 Real Estate
$10.00 −0.10 (−0.99%)
Oct 27 4:00 PM ET · prev $10.10
Next earnings
Nov 13
in 17 days
1 year
−17.7%
from $12.15 · Oct 28
30 days
−2.5%
from $10.26
52-week range
$10.00–12.19
−18% from high · low Oct 14
Avg volume 20D
19.4K
Oct 15 spike 320.4K
Short interest
265
+3.9%
Days to cover
1.0
at average volume
Insider net
−$2.1M
0 buyers · 1 seller · 12 mo
Filing reports
4
analyzed by SecBot
SecBot read BEARISH 2 reports · 90 days
Balance 1 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 13, 2026
Strongest BEARISH Copper Property CTL Pass Through Trust filed a lawsuit in Massachusetts Superior Court against Anton…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $2.1M.

  • Short sellersSTEADY

    Short interest +3.9% to 265 shares. 1.0 days to cover.

  • TrendDOWNTREND

    5% below its 50-day average. New closing low $10.00 on Oct 27.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 7, 2026 SEC
Copper Property CTL Pass Through Trust filed its monthly reporting package for September 2026, disclosing a total cash…
8-K — Impact 3/10
Aug 26, 2026 SEC
Copper Property CTL Pass Through Trust filed a lawsuit in Massachusetts Superior Court against Anton Melchionda and…
8-K — Impact 7/10
Jul 28, 2026 Insider
Silver Point Capital L.P. sold 200,000 shares
10%+ Owner @ $10.55 ($2.1M)
May 22, 2026 Drug approval
EMA: Human medicines European public assessment report (EPAR): Deqtynet, copper (64Cu) oxodotreotide, Status: Opinion
Human medicines European public assessment report (EPAR): Deqtynet, copper (64Cu) oxodotreotide, Sta
Apr 7, 2026 SEC
Copper Property CTL Pass Through Trust released Q4 2025 Master Lease store performance disclosures, providing…
8-K — Impact 3/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 13, 2026
Earnings date
CPPTL Q3 2026 Earnings Scheduled — 2026-11-13
Recent
May 22, 2026
Drug approval
EMA: Human medicines European public assessment report (EPAR): Deqtynet, copper (64Cu) oxodotreotide, Status: Opinion
Human medicines European public assessment report (EPAR): Deqtynet, copper (64Cu) oxodotreotide, Status: Opinion

Insider ledger

Form 4
$0
bought · 0 insiders
$2.1M
sold · 1 insider
DateInsiderTypeValue
Jul 28, 2026
Silver Point Capital L.P.
10%+ Owner
SELL$2.1M

Earnings setup

Estimates
Nov 13
reports in 17 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
265
shares short
+3.9%
vs prior settlement
1.0
days to cover

SecBot reports

4 filings · 0 bullish · 1 bearish · 3 neutral
All CPPTL filing & press-release reports (4)